抗血管紧张素Ⅱ1型受体自身抗体检测方法及其临床评价

目的：建立抗血管紧张素Ⅰ1型（AT1）受体身身抗体ELISA，评价抗AT1自身抗体与高血压的关系。方法：以合成的AT1受体细胞外第二环功能表位肽段（AT1 165－191位氨基酸）作抗原，建立ELISA，检测98例难治性高血压患者、96例非难治性高血压患者和40例正常人血清中AT1受体自身抗体。结果：阳性对照表批内变异系数（CV）和批间CV分别为6．6％、9．7％；用抗原吸收后，吸光度值降低60％，难治性高血压患者中抗AT1受体自身抗体阳性率为42．8％（42／98），明显高于非难治性高血压组10．42％（10／96）和正常血压对照组7．5％（3／40），结论：所建抗AT1受体自身抗体撞接ELISA，操作简便，检测该抗体有助于揭示难治性高血压的原因和指导降压药物的选择。

The clinical evaluation for the method determining the autoantibody against AT1-receptor using synthesized peptide

Objective To establish the method to screen the autoantibody against the AT1 receptor by ELISA and to assess the role of the autoantibodies in hypertension.Method The peptid of functional epitiope of the second extracellular loops (amino acid sequence from 165 to 191) of AT1 receptor was synthesized.This epitope was used as antigens to eevelop an indirect ELISA to screen the autoantibody of AT1 receptor.The autoantibody to AT1 receptor in 98 patients with refractory hypertension,96 patients with ordinary hypertension and 40 normal control,were detected.Results The CVs of intra and inter assay were 6.6% and 9.7% respectively in positive control group.Also,values of the A decreased 60% after absorption by antigens. Of the 98 patients,the autoantibody against AT1 receptor was positive in 41 patients(41.8%),while in control group,the positive rate was 7.5%.There was a significant difference between the patient and control group.Conclusion The method developed in this study is simple and stable to screen the autoantibodies of AT1 receptor in hypertensive patients. Thus, it is useful for clinicians in choosing proper drugs for the treatment of hypertension.